Evidence map›Paper›PMID 19004043›Full record

ArticleThe Journal of rheumatology2009

Systemic lupus erythematosus features in rheumatoid arthritis and their effect on overall mortality.

Murat Icen, Paulo J Nicola, Hilal Maradit-Kremers, Cynthia S Crowson, Terry M Therneau, Eric L Matteson, Sherine E Gabriel

Abstract read
In one paragraph

Article in The Journal of rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Serum Metabolic Fingerprints Characterize Systemic Lupus Erythematosus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Recent advances in the genetics of systemic lupus erythematosus.Expert review of clinical immunology · 2010
    Review
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Murat IcenDepartment of Health Sciences Research, Mayo Foundation, 200 First St. SW, Rochester, MN 55905, USA.
Paulo J Nicola
Hilal Maradit-Kremers
Cynthia S Crowson
Terry M Therneau
Eric L Matteson
Sherine E Gabriel

Funding

HEART DISEASE IN RHEUMATOID ARTHRITISR01AR046849 · NIAMS · MAYO CLINIC ROCHESTER · PI CROWSON, CYNTHIA S · 2000 to 2022
$11.3M
ROCHESTER EPIDEMIOLOGY PROJECTR01AR030582 · NIAMS · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A · 1986 to 2009
$5.1M
NIAMS NIH HHS AR-30582NIAMS NIH HHS R01 AR030582NIAMS NIH HHS R01 AR046849NIAMS NIH HHS R01 AR46849
6 · The paper itself

Abstract

objectiveFeatures of systemic lupus erythematosus (SLE) are commonly observed in patients with rheumatoid arthritis (RA). However, their frequency and clinical significance are uncertain. We examined the frequency of SLE features in RA and their effect on overall mortality.

methodsWe assembled a population-based incidence cohort of subjects aged >or=18 years first diagnosed with RA [1987 American College of Rheumatology (ACR) criteria] between 1955 and 1995. Information regarding disease characteristics, therapy, comorbidities, and SLE features (1982 ACR criteria) were collected from the complete inpatient and outpatient medical records. Cox regression models were used to estimate the mortality risk associated with lupus features.

resultsThe study population comprised 603 subjects with incident RA (mean age 58 yrs, 73% women) with a mean followup time of 15 years. By 25 years after RA incidence, >or=4 SLE features were observed in 15.5% of the subjects with RA. After adjustment for age and sex, occurrence of >or=4 SLE features was associated with increased overall mortality [hazard ratio (HR) 5.54, 95% confidence interval (CI) 3.59-8.53].With further adjustment for RA characteristics, therapy, and comorbidities, the association weakened but remained statistically significant (HR 2.56, 95% CI 1.60-4.08). After adjustment for age, sex, RA characteristics, therapy, and comorbidities, thrombocytopenia (2.0, 95% CI 1.2, 3.1) and proteinuria (1.8, 95% CI 1.3, 2.6) were significantly associated with mortality.

conclusionSLE features were common in RA, given sufficient observation time. Subjects with RA who developed >or=4 SLE features had an increased risk of death. Proteinuria and thrombocytopenia were individually associated with an increased mortality risk.

Indexed as

AdultAgedArthritis, RheumatoidComorbidityFemaleHumansIncidenceLupus Erythematosus, SystemicMaleMiddle AgedProportional Hazards ModelsRisk Factors

Identifiers

PMID19004043
PMCPMC2836232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.